Adenomyosis and Fertility: Why Scans Miss It
Three failed transfers, a uterus called "structurally normal" on every ultrasound, and then a suspicion raised almost in passing — that nobody had actually looked for adenomyosis. That sequence is common enough to be a pattern. Adenomyosis is one of the most common reasons a uterus that looks fine on a routine scan behaves like it is not fine during implantation, and it is still, in 2026, a condition most transvaginal ultrasound reports never mention by name. If your workup has been thorough on hormones and embryos but thin on the uterus itself, this is the gap worth closing before the next cycle.
Why did my ultrasound say my uterus is normal if I have adenomyosis?
Because a "normal" ultrasound usually means no fibroids and no obvious masses were seen, not that someone specifically looked for the nine-plus sonographic features that define adenomyosis. Adenomyosis is a diffuse, textural change in the muscle wall of the uterus rather than a discrete lump, so it is easy to miss unless the person scanning is trained to look for it and reports it using standardized terminology.
That gap between "scanned" and "screened for adenomyosis" explains a lot of the confusion patients carry into a fertility workup. A uterus can be free of fibroids, free of polyps, and still have glandular tissue embedded in the muscle wall that is quietly changing how the lining behaves each cycle.
What exactly is adenomyosis, and how is it different from endometriosis or fibroids?
Adenomyosis is the presence of endometrial glands and stroma — the tissue that normally lines the inside of the uterus — growing within the myometrium, the muscular wall itself. This is mechanically different from both conditions patients most often confuse it with. Endometriosis is endometrial-like tissue growing outside the uterus, on the ovaries, peritoneum, or bowel. Fibroids are benign muscle tumors that grow as discrete, usually well-defined masses within or on the uterine wall. Adenomyosis is neither a mass nor a lesion outside the uterus; it is infiltration inside the muscle, and it disrupts a specific structure called the junctional zone — the inner layer of myometrium adjacent to the lining, which normally has its own smooth, thin architecture and its own role in the small contractions that move sperm and, later, help or hinder an embryo settling in.
A review of the leading pathogenesis theories describes two competing explanations: that basal endometrium physically invaginates into the myometrium after tissue injury, or that displaced embryonic cell remnants undergo metaplasia into endometrial-type tissue within the muscle. Neither theory is fully settled, but both converge on the same structural consequence — a junctional zone that thickens, distorts, and stops behaving like normal muscle.
Why do standard scans miss adenomyosis so often?
Three separate problems stack on top of each other. First, for decades the only definitive diagnosis was histology from a hysterectomy specimen — a diagnostic standard that is obviously useless for a woman trying to conceive, so imaging criteria are still catching up to that gold standard. Second, transvaginal ultrasound accuracy for adenomyosis is genuinely operator-dependent; a systematic review comparing ultrasound and MRI against histology found both techniques could be accurate, but performance varied widely study to study, largely tracking the experience of whoever was holding the probe. Third, and most practically, the findings have names that most general ultrasound reports simply never use.
Those names matter because they are what separates a scan that screened for adenomyosis from one that merely ruled out fibroids. An international panel of ultrasound experts published a consensus, known as the MUSA (Morphological Uterus Sonographic Assessment) statement, that defines specific features: asymmetric wall thickening, myometrial cysts, hyperechogenic islands, echogenic subendometrial lines and buds, irregular or interrupted junctional zone, translesional vascularity, and a fan-shaped shadowing pattern. A general obstetric ultrasound looking for fetal anatomy or a fibroid count was never built to catalog any of that. If your report does not use language like this, it almost certainly was not looking for it.
What should I ask my doctor to look for by name?
Ask specifically for a targeted transvaginal ultrasound assessed against MUSA criteria, and ask the report to state explicitly whether junctional-zone thickening, myometrial cysts, asymmetric wall thickening, linear striations, or a "question-mark" uterine contour were present or absent. A report that says "adenomyosis features: not seen" using that language is far more informative than one that says nothing at all, because it tells you someone actually looked.
It is a reasonable, specific request, and any sonographer or reproductive endocrinologist working regularly with fertility patients on Long Island should recognize the terminology immediately. If the answer you get back is vague, that itself is useful information about whether the scan was adequate for this particular question.
Is pelvic MRI actually better than ultrasound for this?
MRI gives a more standardized, less operator-dependent picture, particularly through direct measurement of the junctional zone, which is harder to reliably assess by ultrasound in a uterus that is enlarged, tender, or has co-existing fibroids. A systematic review comparing ultrasound and MRI for adenomyosis, using histology as the reference standard, found both modalities can perform well but that MRI produces more consistent numbers across different readers, which matters when a subtle diffuse process is what you are hunting for.
MRI is not the first step for everyone. It is worth pursuing when an expert ultrasound is inconclusive, when fibroids are large enough to obscure the myometrium on ultrasound, when you are being evaluated after a failed transfer with no other clear cause, or when a surgeon is planning a fertility-preserving procedure and needs to know exactly how much of the uterine wall is involved. Whether to order it, and how to interpret it, is a conversation for your reproductive endocrinologist or OB-GYN, not something to self-refer for repeatedly.
How does adenomyosis actually affect fertility and IVF outcomes?
Several mechanisms have evidence behind them, at different strengths. The clearest structural mechanism is disrupted junctional-zone function: a systematic review and meta-analysis of uterine contractility in adenomyosis found altered patterns of uterine peristalsis compared with women without the disease, which plausibly affects both sperm transport and the mechanical environment an embryo needs to implant. Inflammation and oxidative stress within the affected myometrium are also implicated, alongside progesterone resistance in the eutopic endometrium — a reduced tissue response to progesterone that can misalign the receptive window even when hormone levels look normal on paper. A review of the interaction between estrogen and inflammatory signaling in adenomyosis lays out how local estrogen excess and chronic inflammation can reinforce each other in the same tissue.
On outcomes specifically, two meta-analyses give the clearest numbers available. A 2014 meta-analysis of nine comparative studies found women with adenomyosis had roughly a 28 percent lower likelihood of clinical pregnancy after IVF or ICSI compared with women without it. A separate 2017 meta-analysis of eleven studies covering more than 2,000 women found adenomyosis was associated with lower clinical pregnancy, implantation, and live birth rates, and a higher miscarriage rate. Both are honest about their limits: the underlying studies vary in how adenomyosis was diagnosed, most are retrospective, and an association is not a fixed prognosis for any one person. What these numbers support is a reason to investigate and address adenomyosis specifically, not a number to carry into your own next cycle as if it applies to you individually.
What symptoms should make me ask about this?
The classic pattern is heavy menstrual bleeding, cramping that starts building before the bleed itself rather than arriving with it, a uterus that feels or measures larger or "boggy" on exam, chronic pelvic pressure, and pain with intercourse. Any one of these on its own is common and not diagnostic. The combination — especially heavy bleeding plus pre-menstrual cramping that has been getting worse over months or years — is the pattern worth naming out loud at your next appointment.
A meaningful share of women with adenomyosis, however, have none of these symptoms and find out only through imaging done for an unrelated fertility workup or after a failed transfer. That is precisely why "I have no symptoms" is not a reason to skip the question if implantation has been the sticking point. Absence of symptoms rules out nothing here.
What is actually done about adenomyosis before a fertility treatment?
The most studied intervention for women pursuing IVF is a course of GnRH agonist suppression before embryo transfer, which lowers estrogen and quiets the inflammatory environment in the myometrium for a period before the lining is prepared again. A 2025 systematic review and meta-analysis of ten studies found long-term GnRH agonist pretreatment improved the odds of clinical pregnancy in fresh IVF/ICSI cycles, though the benefit in frozen embryo transfer cycles specifically did not reach statistical significance across the pooled data — a distinction worth raising directly with your reproductive endocrinologist if you are planning a frozen transfer. For women who are not currently trying to conceive, progestin therapy or a levonorgestrel-releasing IUD is commonly used for symptom control — heavy bleeding and pain — rather than for fertility itself. In selected cases with a focal adenomyoma rather than diffuse disease, surgical excision has been studied with reported pregnancy afterward in some series, but it is a decision that belongs with a surgeon experienced in fertility-preserving techniques, weighed against uterine wall integrity for a future pregnancy.
None of this is something to self-manage. Every medication, dose, and surgical decision here belongs with your OB-GYN or reproductive endocrinologist, based on your imaging, your history, and your fertility goals. What can legitimately be worked on alongside that medical plan is the supportive layer: blood flow to the uterus, glycemic control, systemic inflammation, sleep, and stress load. None of that reverses adenomyosis or replaces a suppression protocol, but a body under less inflammatory and metabolic strain is a more cooperative environment for whatever treatment your specialist prescribes — which is the layer we focus on within the Blood Flow & Signaling, Egg & Sperm Quality, and Fertility Environment framework we use with patients in Huntington.
Does having adenomyosis mean I probably have endometriosis too?
Not automatically, but the overlap is real enough that finding one should prompt a deliberate look for the other. Both conditions share estrogen dependence and inflammatory pathways, and case series consistently describe meaningful co-occurrence, particularly in women with deep infiltrating endometriosis. If you have been diagnosed with one and still have unexplained pelvic pain, painful intercourse, or bowel or bladder symptoms around your period, it is worth asking specifically whether the other was ever assessed. We go deeper on the combined picture, including how the two interact through an IVF cycle, in preparing for IVF when adenomyosis and endometriosis coexist, and our PCOS and endometriosis care page covers how we work through that evaluation.
How is this different from a lining that is just too thin, or from unexplained implantation failure?
A thin lining and adenomyosis are distinct problems that sometimes get lumped together because they both show up as implantation trouble. Lining thickness is a measurement; adenomyosis is a structural and inflammatory change in the muscle underneath that lining. You can have a lining that measures well on ultrasound and still have adenomyosis disrupting the mechanics or the inflammatory environment beneath it, which is part of why implantation failure gets labeled "unexplained" more often than it should. If a thin lining has also been part of your picture, our piece on what actually causes a uterine lining to run thin is a useful companion read, and if you have already been through the standard workup with no answer, why implantation keeps failing when everything looks normal walks through the fuller list of causes worth ruling out, adenomyosis among them. The inflammatory side of that picture — separate from adenomyosis but often present alongside it — is covered in how systemic inflammation affects fertility.
What should I actually do next if I suspect this?
If you have had a failed transfer with no other clear explanation, heavy or worsening periods, or a uterus described only as "normal" without any mention of MUSA features, bring the specific request to your next appointment: a targeted transvaginal ultrasound read against MUSA criteria, or a pelvic MRI with junctional-zone measurement if ultrasound is inconclusive. Bring the language from this article if it helps the conversation move faster. Patients across Long Island frequently arrive at a fertility evaluation with a stack of normal reports and a uterus no one has actually screened for this, and naming the right test is often the fastest way to stop guessing.
If adenomyosis has already been diagnosed and a transfer has already failed because of it, the next conversation is about protocol, not about screening — our guide on what to change after a failed transfer with severe adenomyosis picks up exactly there. And if you are earlier in the process and want the metabolic and inflammatory side of your picture mapped out alongside whatever your reproductive endocrinologist is doing medically, our IVF and IUI support program is built for that layer of the work.
Adenomyosis is common, frequently missed by routine imaging, and genuinely relevant to why a transfer can fail in a uterus repeatedly called normal — but a diagnosis is a reason to get a more precise plan, not a verdict on whether you will conceive. The most useful next step is almost always the same: ask for the specific imaging language, get a specialist to read it, and treat the finding as one piece of a fuller fertility picture rather than the whole story.
This article is for general educational purposes and is not a substitute for individualized medical care. Imaging interpretation, diagnosis, and any medication or surgical decisions belong with your OB-GYN or reproductive endocrinologist, based on your own history.
East to West Fertility is a systems biology fertility clinic in Huntington, Long Island, serving patients across Long Island, NYC, and beyond. Learn more about our Metabolic & Immune Fertility Evaluation or call 631-416-4940.
The adenomyosis signal does not stop at conception. Our review of endometriosis and adenomyosis in pregnancy covers the miscarriage and placental associations reported after a positive test, and what surveillance those findings reasonably justify.
References:
García-Solares J, Donnez J, Donnez O, Dolmans MM. "Pathogenesis of uterine adenomyosis: invagination or metaplasia?" Fertility and Sterility, 2018;109(3):371-379.
Harmsen MJ, Van den Bosch T, de Leeuw RA, et al. "Consensus on revised definitions of Morphological Uterus Sonographic Assessment (MUSA) features of adenomyosis: results of modified Delphi procedure." Ultrasound in Obstetrics & Gynecology, 2022;60(1):118-131.
Champaneria R, Abedin P, Daniels J, Balogun M, Khan KS. "Ultrasound scan and magnetic resonance imaging for the diagnosis of adenomyosis: systematic review comparing test accuracy." Acta Obstetricia et Gynecologica Scandinavica, 2010;89(11):1374-1384. (23 studies, 2,312 women.)
Vidal A, Tepasse P, Vinayahalingam V, et al. "Uterine Contractility Changes in Adenomyosis: Evidence from a Systematic Review and Meta-Analysis." Biomedicines, 2025;13(11):2728.
Li F, Wang HJ, Zhang Y, et al. "The interaction between inflammation and estrogen in adenomyosis: from molecular mechanisms to therapeutic strategies." Seminars in Immunopathology, 2026;48(1):10.
Vercellini P, Consonni D, Dridi D, Bracco B, Frattaruolo MP, Somigliana E. "Uterine adenomyosis and in vitro fertilization outcome: a systematic review and meta-analysis." Human Reproduction, 2014;29(5):964-977. (9 comparative studies.)
Younes G, Tulandi T. "Effects of adenomyosis on in vitro fertilization treatment outcomes: a meta-analysis." Fertility and Sterility, 2017;108(3):483-490.e3. (11 comparative studies, 2,054 women.)
Galati G, Olivieri C, Cosentino M, et al. "Medical treatment before in-vitro fertilization in patients with adenomyosis: a systematic review and meta-analysis." Journal of Assisted Reproduction and Genetics, 2025;42(2):381-388. (10 studies.)
